2 of the top ASX healthcare shares to own right now

These two are standouts in the ASX healthcare space.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking to add high-quality ASX healthcare shares to your portfolio, experts say there are two standout options to consider: ResMed Inc (ASX: RMD) and CSL Ltd (ASX: CSL).

Both of these healthcare giants are well-positioned for growth and are favourites among leading analysts.

And with the market gyrating in recent weeks, some investors might be searching for individual names in the crowd.

Here's what the experts are saying on these 2 top ASX healthcare shares.

ASX healthcare shares in favour

ResMed is in the sleep disorder treatment business. It has been on the radar for many investors in 2024, having surged 42% this year. At the time of writing, it trades at $36.09 per share.

Analysts at Morgans believe ResMed is well-positioned for future growth. Even in the face of emerging weight-loss drugs that could potentially impact the healthcare sector.

But Morgans is confident that these drugs will have little impact on the "large, underserved sleep disorder breathing market" that ResMed dominates.

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALL1 Sep 20235 Sep 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

In its most recent quarterly results, ResMed posted 9% revenue growth to US$1.2 billion and a 350 basis-point improvement in its gross margin.

The ASX healthcare share is also rated as a buy from consensus, according to CommSec.

CSL for the long-term

CSL is another standout in the ASX healthcare space. Having climbed 5% into the green this year, the company has also paid dividends of $3.80 per share in the last 12 months.

Bell Potter rates the ASX healthcare share a buy, citing its positive margin outlook and strong earnings growth prospects.

CSL's transition into a "margin recovery phase" is expected to drive above-market earnings growth in the coming years.

Bell Potter highlights that CSL trades at a 12-month forward price-to-earnings (PE) ratio of around less than 30 times.

This is a discount compared to its ten-year average of 31 times and its five-year average of 35 times.

Bell Potter has a buy rating on CSL and a price target of $327.42, signalling potential for 8% upside at the time of writing.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Sep 20235 Sep 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

CSL's long-standing history as a high-performing ASX healthcare share also earns it high marks from the broker.

Given the company's proven quality and growth prospects, we believe significant upside remains.

Foolish takeaway

These 2 ASX healthcare shares are rated as top buys according to leading brokers. Each company has plenty going on and could be well positioned.

CSL shares are up 11% in the last twelve months. Whereas Resmed shares have climbed more than 51% over that time.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning...

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

Read more »